ICD-10-PCS FY2026 code changes

Historical release · ICD-10-PCS FY2026 · Effective October 1, 2025 – March 31, 2026 ICD-10-PCS FY2027 is the release in force (effective October 1, 2026).

Part of FY2026 coding changes

Every recorded ICD-10-PCS code addition, deletion, description revision, billable-status change and tabular-instruction change for FY2026, effective October 1, 2025.

These changes are based on recorded release data. MedCoder does not generate coding changes with AI.

Release: ICD-10-PCS FY2026
Effective: October 1, 2025
Code set period: 2025-10-01 through 2026-03-31

FY2026 at a glance

156Added156 of them valid for submission 27Deleted27 were valid for submission

Explore the complete recorded change list →

Compare a code

Enter any ICD-10-PCS code to see what this release does to it: added, deleted, description revised, billable status changed, new child codes, or no change at all. The answer is a lookup against the recorded changes below — nothing is generated.

Deleted codes — what to report instead

These codes leave the code set on October 1, 2025. Where a successor was determined from the source files it is named below; where none was, that is stated rather than guessed.

No successor was determined for these codes.

FY2025 (April) code	FY2025 (April) description	FY2026 status	Effective
X2A5312	Cerebral Embolic Filtration, Dual Filter in Innominate Artery and Left Common Carotid Artery, Percutaneous Approach, New Technology Group 2	Deleted — not valid for submission	October 1, 2025
X2A6325	Cerebral Embolic Filtration, Single Deflection Filter in Aortic Arch, Percutaneous Approach, New Technology Group 5	Deleted — not valid for submission	October 1, 2025
X2AH336	Cerebral Embolic Filtration, Extracorporeal Flow Reversal Circuit from Right Common Carotid Artery, Percutaneous Approach, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
X2AJ336	Cerebral Embolic Filtration, Extracorporeal Flow Reversal Circuit from Left Common Carotid Artery, Percutaneous Approach, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
XW03306	Introduction of Brexanolone into Peripheral Vein, Percutaneous Approach, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
XW03326	Introduction of Nerinitide into Peripheral Vein, Percutaneous Approach, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
XW03336	Introduction of Durvalumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
XW03366	Introduction of Lefamulin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
XW033A6	Introduction of Cefiderocol Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
XW033B6	Introduction of Omadacycline Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
XW033C6	Introduction of Eculizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
XW033D6	Introduction of Atezolizumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
XW033E6	Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
XW033F6	Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
XW04306	Introduction of Brexanolone into Central Vein, Percutaneous Approach, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
XW04326	Introduction of Nerinitide into Central Vein, Percutaneous Approach, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
XW04336	Introduction of Durvalumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
XW04366	Introduction of Lefamulin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
XW043A6	Introduction of Cefiderocol Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
XW043B6	Introduction of Omadacycline Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
XW043C6	Introduction of Eculizumab into Central Vein, Percutaneous Approach, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
XW043D6	Introduction of Atezolizumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
XW043E6	Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
XW043F6	Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
XW0DX66	Introduction of Lefamulin Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
XXE5XN6	Measurement of Infection, Positive Blood Culture Fluorescence Hybridization for Organism Identification, Concentration and Susceptibility, New Technology Group 6	Deleted — not valid for submission	October 1, 2025
XXEBXQ6	Measurement of Infection, Lower Respiratory Fluid Nucleic Acid-base Microbial Detection, New Technology Group 6	Deleted — not valid for submission	October 1, 2025

The full recorded change list

Every recorded change, grouped by what kind of change it is. Each entry shows the code's own description first; tabular instructions and relationship text are labeled separately beneath it.

Added to the code set (156)

00H033J — Insertion of Infusion Device into Brain, Temporary, Percutaneous Approach
00P207Z — Removal of Autologous Tissue Substitute from Dura Mater, Open Approach
00P20JZ — Removal of Synthetic Substitute from Dura Mater, Open Approach
00P20KZ — Removal of Nonautologous Tissue Substitute from Dura Mater, Open Approach
00PT07Z — Removal of Autologous Tissue Substitute from Spinal Meninges, Open Approach
00PT0JZ — Removal of Synthetic Substitute from Spinal Meninges, Open Approach
00PT0KZ — Removal of Nonautologous Tissue Substitute from Spinal Meninges, Open Approach
00W207Z — Revision of Autologous Tissue Substitute in Dura Mater, Open Approach
00W20JZ — Revision of Synthetic Substitute in Dura Mater, Open Approach
00W20KZ — Revision of Nonautologous Tissue Substitute in Dura Mater, Open Approach
00WT07Z — Revision of Autologous Tissue Substitute in Spinal Meninges, Open Approach
00WT0JZ — Revision of Synthetic Substitute in Spinal Meninges, Open Approach
00WT0KZ — Revision of Nonautologous Tissue Substitute in Spinal Meninges, Open Approach
02UW3LZ — Supplement Thoracic Aorta, Descending with Intraluminal Device, Endovascular Anchors, Percutaneous Approach
031209Y — Bypass Innominate Artery to Upper Artery with Autologous Venous Tissue, Open Approach
03120AY — Bypass Innominate Artery to Upper Artery with Autologous Arterial Tissue, Open Approach
03120JY — Bypass Innominate Artery to Upper Artery with Synthetic Substitute, Open Approach
03120KY — Bypass Innominate Artery to Upper Artery with Nonautologous Tissue Substitute, Open Approach
03120ZY — Bypass Innominate Artery to Upper Artery, Open Approach
04U03LZ — Supplement Abdominal Aorta with Intraluminal Device, Endovascular Anchors, Percutaneous Approach
09XK0Z1 — Transfer Nasal Mucosa and Soft Tissue to Frontal Bone, Open Approach
09XK0Z2 — Transfer Nasal Mucosa and Soft Tissue to Ethmoid Bone, Open Approach
09XK0Z3 — Transfer Nasal Mucosa and Soft Tissue to Sphenoid Bone, Open Approach
09XK0Z4 — Transfer Nasal Mucosa and Soft Tissue to Occipital Bone, Open Approach
09XL0Z1 — Transfer Nasal Turbinate to Frontal Bone, Open Approach
09XL0Z2 — Transfer Nasal Turbinate to Ethmoid Bone, Open Approach
09XL0Z3 — Transfer Nasal Turbinate to Sphenoid Bone, Open Approach
09XL0Z4 — Transfer Nasal Turbinate to Occipital Bone, Open Approach
09XM0Z1 — Transfer Nasal Septum to Frontal Bone, Open Approach
09XM0Z2 — Transfer Nasal Septum to Ethmoid Bone, Open Approach
09XM0Z3 — Transfer Nasal Septum to Sphenoid Bone, Open Approach
09XM0Z4 — Transfer Nasal Septum to Occipital Bone, Open Approach
0C1S0E4 — Bypass Larynx to Cutaneous with Endotracheal Airway, Open Approach
0C1S0F4 — Bypass Larynx to Cutaneous with Tracheostomy Device, Open Approach
0C1S0Z4 — Bypass Larynx to Cutaneous, Open Approach
0C1S3E4 — Bypass Larynx to Cutaneous with Endotracheal Airway, Percutaneous Approach
0C1S3F4 — Bypass Larynx to Cutaneous with Tracheostomy Device, Percutaneous Approach
0C1S3Z4 — Bypass Larynx to Cutaneous, Percutaneous Approach
0F198D3 — Bypass Common Bile Duct to Duodenum with Intraluminal Device, Via Natural or Artificial Opening Endoscopic
0F198Z3 — Bypass Common Bile Duct to Duodenum, Via Natural or Artificial Opening Endoscopic
0RRJ008 — Replacement of Right Shoulder Joint with Reverse Ball and Socket Synthetic Substitute, Subscapularis-sparing Technique, Open Approach
0RRJ0J8 — Replacement of Right Shoulder Joint with Synthetic Substitute, Subscapularis-sparing Technique, Open Approach
0RRK008 — Replacement of Left Shoulder Joint with Reverse Ball and Socket Synthetic Substitute, Subscapularis-sparing Technique, Open Approach
0RRK0J8 — Replacement of Left Shoulder Joint with Synthetic Substitute, Subscapularis-sparing Technique, Open Approach
0SRC07D — Replacement of Right Knee Joint with Autologous Tissue Substitute, Medial Meniscus, Open Approach
0SRC07E — Replacement of Right Knee Joint with Autologous Tissue Substitute, Lateral Meniscus, Open Approach
0SRC0KD — Replacement of Right Knee Joint with Nonautologous Tissue Substitute, Medial Meniscus, Open Approach
0SRC0KE — Replacement of Right Knee Joint with Nonautologous Tissue Substitute, Lateral Meniscus, Open Approach
0SRD07D — Replacement of Left Knee Joint with Autologous Tissue Substitute, Medial Meniscus, Open Approach
0SRD07E — Replacement of Left Knee Joint with Autologous Tissue Substitute, Lateral Meniscus, Open Approach
0SRD0KD — Replacement of Left Knee Joint with Nonautologous Tissue Substitute, Medial Meniscus, Open Approach
0SRD0KE — Replacement of Left Knee Joint with Nonautologous Tissue Substitute, Lateral Meniscus, Open Approach
5A05A6M — Intraoperative Cerebral Embolic Filtration, Single Capture Filter
5A05A6N — Intraoperative Cerebral Embolic Filtration, Dual Capture Filter
5A05A6P — Intraoperative Cerebral Embolic Filtration, Single Deflection Filter
5A05A6Q — Intraoperative Cerebral Embolic Filtration, Extracorporeal Flow Reversal Circuit
6A4T00A — Hypothermia of Urinary System using Donor Organ Protective Thermal Insulation, Single, Intraoperative
8E0ZXGP — External Confocal Microscopy, Intraoperative Specimen Analysis
F08D5AZ — Wound Management Treatment of Integumentary System - Head and Neck using Negative Pressure Therapy
F08F5AZ — Wound Management Treatment of Integumentary System - Upper Back / Upper Extremity using Negative Pressure Therapy
F08G5AZ — Wound Management Treatment of Integumentary System - Lower Back / Lower Extremity using Negative Pressure Therapy
F08H5AZ — Wound Management Treatment of Integumentary System - Whole Body using Negative Pressure Therapy
F08J5AZ — Wound Management Treatment of Musculoskeletal System - Head and Neck using Negative Pressure Therapy
F08K5AZ — Wound Management Treatment of Musculoskeletal System - Upper Back / Upper Extremity using Negative Pressure Therapy
F08L5AZ — Wound Management Treatment of Musculoskeletal System - Lower Back / Lower Extremity using Negative Pressure Therapy
F08M5AZ — Wound Management Treatment of Musculoskeletal System - Whole Body using Negative Pressure Therapy
X05233B — Destruction of Thoracic Sympathetic Nerve, Cardiac Plexus using Radiofrequency Ablation, Percutaneous Approach, New Technology Group 11
X053X4B — Destruction of Brain using Focused Ultrasound Therapy, External Approach, New Technology Group 11
X27339B — Dilation of Right Pulmonary Artery with Expandable Intraluminal Device, Percutaneous Approach, New Technology Group 11
X27439B — Dilation of Left Pulmonary Artery with Expandable Intraluminal Device, Percutaneous Approach, New Technology Group 11
X27535B — Dilation of Right Subclavian Vein with Cell Impermeable Intraluminal Device, Percutaneous Approach, New Technology Group 11
X27635B — Dilation of Left Subclavian Vein with Cell Impermeable Intraluminal Device, Percutaneous Approach, New Technology Group 11
X27735B — Dilation of Right Axillary Vein with Cell Impermeable Intraluminal Device, Percutaneous Approach, New Technology Group 11
X27835B — Dilation of Left Axillary Vein with Cell Impermeable Intraluminal Device, Percutaneous Approach, New Technology Group 11
X27935B — Dilation of Right Brachial Vein with Cell Impermeable Intraluminal Device, Percutaneous Approach, New Technology Group 11
X27A35B — Dilation of Left Brachial Vein with Cell Impermeable Intraluminal Device, Percutaneous Approach, New Technology Group 11
X27B35B — Dilation of Right Basilic Vein with Cell Impermeable Intraluminal Device, Percutaneous Approach, New Technology Group 11
X27C35B — Dilation of Left Basilic Vein with Cell Impermeable Intraluminal Device, Percutaneous Approach, New Technology Group 11
X27D35B — Dilation of Right Cephalic Vein with Cell Impermeable Intraluminal Device, Percutaneous Approach, New Technology Group 11
X27E35B — Dilation of Left Cephalic Vein with Cell Impermeable Intraluminal Device, Percutaneous Approach, New Technology Group 11
X27W39B — Dilation of Thoracic Aorta, Descending with Expandable Intraluminal Device, Percutaneous Approach, New Technology Group 11
X27X39B — Dilation of Thoracic Aorta, Ascending/Arch with Expandable Intraluminal Device, Percutaneous Approach, New Technology Group 11
X28F3WB — Division of Aortic Valve using Leaflet Laceration, Radiofrequency Energy, Percutaneous Approach, New Technology Group 11
X2AH34B — Right Common Carotid Artery Cerebral Embolic Filtration, Single Integrated Distal Filter, Percutaneous Approach, New Technology Group 11
X2AJ34B — Left Common Carotid Artery Cerebral Embolic Filtration, Single Integrated Distal Filter, Percutaneous Approach, New Technology Group 11
X2AK34B — Right Internal Carotid Artery Cerebral Embolic Filtration, Single Integrated Distal Filter, Percutaneous Approach, New Technology Group 11
X2AL34B — Left Internal Carotid Artery Cerebral Embolic Filtration, Single Integrated Distal Filter, Percutaneous Approach, New Technology Group 11
X2H03BB — Insertion of Volume Sensor Management Device into Inferior Vena Cava, Percutaneous Approach, New Technology Group 11
X2H13XB — Insertion of Temporary Phrenic Nerve/Diaphragm Stimulation Electrodes into Superior Vena Cava, Percutaneous Approach, New Technology Group 11
X2HN37B — Insertion of Endocardiac Pacing Electrode into Left Ventricle, Percutaneous Approach, New Technology Group 11
X2HP38B — Insertion of Temporary Intraluminal Device into Right Anterior Tibial Artery, Percutaneous Approach, New Technology Group 11
X2HQ38B — Insertion of Temporary Intraluminal Device into Left Anterior Tibial Artery, Percutaneous Approach, New Technology Group 11
X2HR38B — Insertion of Temporary Intraluminal Device into Right Posterior Tibial Artery, Percutaneous Approach, New Technology Group 11
X2HS38B — Insertion of Temporary Intraluminal Device into Left Posterior Tibial Artery, Percutaneous Approach, New Technology Group 11
X2HT38B — Insertion of Temporary Intraluminal Device into Right Peroneal Artery, Percutaneous Approach, New Technology Group 11
X2HU38B — Insertion of Temporary Intraluminal Device into Left Peroneal Artery, Percutaneous Approach, New Technology Group 11
X2VY06B — Restriction of Thoracic Aortic Arch and Descending Thoracic Aorta using Uncovered Intraluminal Device with Support Cuff, Open Approach, New Technology Group 11
XDJ07LB — Inspection of Upper Intestinal Tract using Ingestible Capsule with Light Absorption Sensor, Via Natural or Artificial Opening, New Technology Group 11
XHH80HB — Insertion of Ultrasound Transmitter and Battery for Endocardiac Pacing Electrode into Chest Subcutaneous Tissue and Fascia, Open Approach, New Technology Group 11
XNH60HB — Insertion of Bone-Density-Specific Thread and Porosity Pattern Internal Fixation Device into Right Pelvic Bone, Open Approach, New Technology Group 11
XNH63HB — Insertion of Bone-Density-Specific Thread and Porosity Pattern Internal Fixation Device into Right Pelvic Bone, Percutaneous Approach, New Technology Group 11
XNH70HB — Insertion of Bone-Density-Specific Thread and Porosity Pattern Internal Fixation Device into Left Pelvic Bone, Open Approach, New Technology Group 11
XNH73HB — Insertion of Bone-Density-Specific Thread and Porosity Pattern Internal Fixation Device into Left Pelvic Bone, Percutaneous Approach, New Technology Group 11
XNSN0HB — Reposition Right Pelvic Bone with Bone-Density-Specific Thread and Porosity Pattern Internal Fixation Device, Open Approach, New Technology Group 11
XNSN3HB — Reposition Right Pelvic Bone with Bone-Density-Specific Thread and Porosity Pattern Internal Fixation Device, Percutaneous Approach, New Technology Group 11
XNSP0HB — Reposition Left Pelvic Bone with Bone-Density-Specific Thread and Porosity Pattern Internal Fixation Device, Open Approach, New Technology Group 11
XNSP3HB — Reposition Left Pelvic Bone with Bone-Density-Specific Thread and Porosity Pattern Internal Fixation Device, Percutaneous Approach, New Technology Group 11
XRG10RB — Fusion of Cervical Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 11
XRG13RB — Fusion of Cervical Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 11
XRG14RB — Fusion of Cervical Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 11
XRG20RB — Fusion of 2 or more Cervical Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 11
XRG23RB — Fusion of 2 or more Cervical Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 11
XRG24RB — Fusion of 2 or more Cervical Vertebral Joints using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 11
XRG40RB — Fusion of Cervicothoracic Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Open Approach, New Technology Group 11
XRG43RB — Fusion of Cervicothoracic Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Approach, New Technology Group 11
XRG44RB — Fusion of Cervicothoracic Vertebral Joint using Custom-Made Anatomically Designed Interbody Fusion Device, Percutaneous Endoscopic Approach, New Technology Group 11
XRGE0HB — Fusion of Right Sacroiliac Joint using Bone-Density-Specific Thread and Porosity Pattern Internal Fixation Device, Open Approach, New Technology Group 11
XRGE3HB — Fusion of Right Sacroiliac Joint using Bone-Density-Specific Thread and Porosity Pattern Internal Fixation Device, Percutaneous Approach, New Technology Group 11
XRGF0HB — Fusion of Left Sacroiliac Joint using Bone-Density-Specific Thread and Porosity Pattern Internal Fixation Device, Open Approach, New Technology Group 11
XRGF3HB — Fusion of Left Sacroiliac Joint using Bone-Density-Specific Thread and Porosity Pattern Internal Fixation Device, Percutaneous Approach, New Technology Group 11
XRH10GB — Insertion of Molybdenum Rhenium Alloy Spinal Stabilization Device into Cervical Vertebral Joint, Open Approach, New Technology Group 11
XRH13GB — Insertion of Molybdenum Rhenium Alloy Spinal Stabilization Device into Cervical Vertebral Joint, Percutaneous Approach, New Technology Group 11
XRH14GB — Insertion of Molybdenum Rhenium Alloy Spinal Stabilization Device into Cervical Vertebral Joint, Percutaneous Endoscopic Approach, New Technology Group 11
XRH20GB — Insertion of Molybdenum Rhenium Alloy Spinal Stabilization Device into 2 or more Cervical Vertebral Joints, Open Approach, New Technology Group 11
XRH23GB — Insertion of Molybdenum Rhenium Alloy Spinal Stabilization Device into 2 or more Cervical Vertebral Joints, Percutaneous Approach, New Technology Group 11
XRH24GB — Insertion of Molybdenum Rhenium Alloy Spinal Stabilization Device into 2 or more Cervical Vertebral Joints, Percutaneous Endoscopic Approach, New Technology Group 11
XRH40GB — Insertion of Molybdenum Rhenium Alloy Spinal Stabilization Device into Cervicothoracic Vertebral Joint, Open Approach, New Technology Group 11
XRH43GB — Insertion of Molybdenum Rhenium Alloy Spinal Stabilization Device into Cervicothoracic Vertebral Joint, Percutaneous Approach, New Technology Group 11
XRH44GB — Insertion of Molybdenum Rhenium Alloy Spinal Stabilization Device into Cervicothoracic Vertebral Joint, Percutaneous Endoscopic Approach, New Technology Group 11
XRH60GB — Insertion of Molybdenum Rhenium Alloy Spinal Stabilization Device into Thoracic Vertebral Joint, Open Approach, New Technology Group 11
XRH63GB — Insertion of Molybdenum Rhenium Alloy Spinal Stabilization Device into Thoracic Vertebral Joint, Percutaneous Approach, New Technology Group 11
XRH64GB — Insertion of Molybdenum Rhenium Alloy Spinal Stabilization Device into Thoracic Vertebral Joint, Percutaneous Endoscopic Approach, New Technology Group 11
XW013TB — Introduction of Rozanolixizumab-noli Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 11
XW033FB — Introduction of Valoctocogene Roxaparvovec-rvox into Peripheral Vein, Percutaneous Approach, New Technology Group 11
XW033PB — Introduction of Aztreonam-avibactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 11
XW033QB — Introduction of Iloprost into Peripheral Vein, Percutaneous Approach, New Technology Group 11
XW033RB — Introduction of Letetresgene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 11
XW033WB — Introduction of Fosfomycin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 11
XW043FB — Introduction of Valoctocogene Roxaparvovec-rvox into Central Vein, Percutaneous Approach, New Technology Group 11
XW043PB — Introduction of Aztreonam-avibactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 11
XW043QB — Introduction of Iloprost into Central Vein, Percutaneous Approach, New Technology Group 11
XW043RB — Introduction of Letetresgene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 11
XW043WB — Introduction of Fosfomycin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 11
XW0DXVB — Introduction of Xanomeline and Trospium Chloride into Mouth and Pharynx, External Approach, New Technology Group 11
XW0U0XB — Introduction of Peptide Enhanced Bone Void Filler into Joints, Open Approach, New Technology Group 11
XW0U3XB — Introduction of Peptide Enhanced Bone Void Filler into Joints, Percutaneous Approach, New Technology Group 11
XW0U4XB — Introduction of Peptide Enhanced Bone Void Filler into Joints, Percutaneous Endoscopic Approach, New Technology Group 11
XW133SB — Transfusion of Mozafancogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 11
XW133YB — Transfusion of Nonautologous (Human) Fibrinogen Concentrate, Shelf-stable into Peripheral Vein, Percutaneous Approach, New Technology Group 11
XW143SB — Transfusion of Mozafancogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 11
XW143YB — Transfusion of Nonautologous (Human) Fibrinogen Concentrate, Shelf-stable into Central Vein, Percutaneous Approach, New Technology Group 11
XX2KXDB — Monitoring of Interstitial Glucose, Wearable Sensor, External Approach, New Technology Group 11
XXA539B — Circulatory Filtration, Ticagrelor, Percutaneous Approach, New Technology Group 11
XXE5XBB — Measurement of Infection and Immune Response, Gene Expression Testing System, New Technology Group 11
XXEZXAB — Measurement of Macronutrient Content, Computer-aided Assessment for Nutrition Management, New Technology Group 11
XXEZXCB — Measurement of Infection, Computer-aided Triage and Notification, New Technology Group 11

Removed from the code set (27)

X2A5312 — Cerebral Embolic Filtration, Dual Filter in Innominate Artery and Left Common Carotid Artery, Percutaneous Approach, New Technology Group 2
X2A6325 — Cerebral Embolic Filtration, Single Deflection Filter in Aortic Arch, Percutaneous Approach, New Technology Group 5
X2AH336 — Cerebral Embolic Filtration, Extracorporeal Flow Reversal Circuit from Right Common Carotid Artery, Percutaneous Approach, New Technology Group 6
X2AJ336 — Cerebral Embolic Filtration, Extracorporeal Flow Reversal Circuit from Left Common Carotid Artery, Percutaneous Approach, New Technology Group 6
XW03306 — Introduction of Brexanolone into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW03326 — Introduction of Nerinitide into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW03336 — Introduction of Durvalumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW03366 — Introduction of Lefamulin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033A6 — Introduction of Cefiderocol Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033B6 — Introduction of Omadacycline Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033C6 — Introduction of Eculizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033D6 — Introduction of Atezolizumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033E6 — Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033F6 — Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW04306 — Introduction of Brexanolone into Central Vein, Percutaneous Approach, New Technology Group 6
XW04326 — Introduction of Nerinitide into Central Vein, Percutaneous Approach, New Technology Group 6
XW04336 — Introduction of Durvalumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6
XW04366 — Introduction of Lefamulin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
XW043A6 — Introduction of Cefiderocol Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
XW043B6 — Introduction of Omadacycline Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
XW043C6 — Introduction of Eculizumab into Central Vein, Percutaneous Approach, New Technology Group 6
XW043D6 — Introduction of Atezolizumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6
XW043E6 — Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW043F6 — Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW0DX66 — Introduction of Lefamulin Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 6
XXE5XN6 — Measurement of Infection, Positive Blood Culture Fluorescence Hybridization for Organism Identification, Concentration and Susceptibility, New Technology Group 6
XXEBXQ6 — Measurement of Infection, Lower Respiratory Fluid Nucleic Acid-base Microbial Detection, New Technology Group 6

Sources

Official source data

Publisher: Centers for Medicare & Medicaid Services (CMS) and the National Center for Health Statistics (CDC/NCHS)
Release: ICD-10-PCS FY2026
Source file: 2026-icd-10-pcs-codes-file.zip
File checksum (SHA-256): 5663f69c57cd42658f26cd0e160876c06a429237a6cc2106d125753b7554027e
Data type: Public domain code descriptions and tabular instructions. No licensed content.

MedCoder-derived analysis

Change detection: Every addition, deletion, description revision, billable-status change and tabular-instruction change on this page is computed by diffing the two code-description files above, line by line.
Editorial analysis: The grouping of changes into themes, the successor determinations and the coder-impact notes are written by MedCoder against those files. They are not CMS statements.
Independence: MedCoder is an independent coding reference built on public federal data. It is not affiliated with, endorsed by or certified by CMS, and it is not an official CMS coding tool.

Continue

All releases in the Change Ledger